SOX9+LGR5+ was the dominant signature in serous endometrial (63%) and some endometrioid adenocarcinomas (24%) and was positively associated with the ‘Copy-Number high’ molecular subtype from TCGA, as well as the clinically more aggressive stage III and IV adenocarcinomas. This evidence concerns the gene LGR5 and endometrioid adenocarcinoma.